U.S. Luxury Stock News

In August 2026, Labcorp announced it would offer the FDA-cleared Elecsys pTau-217 blood test, the first single-biomarker assay able to both rule in and rule out amyloid pathology associated with Alzheimer’s disease in people 55 and older with cognitive concerns, across primary and specialty care settings. This move broadens Labcorp’s Alzheimer’s testing portfolio and highlights how standardized, minimally invasive blood-based diagnostics could reshape how clinicians assess potential amyloid...

Apollo Global Management has recently been linked to non-binding bids for Shell’s U.S. chemicals business, even as it contends with a disclosed cybersecurity breach involving unauthorized access to its cloud platforms and exposure of sensitive personal data. Together with a proposed US$8,000,000 legal settlement in Delaware Chancery Court, these developments highlight Apollo’s growing operational, legal, and reputational risk footprint alongside its expanding alternatives platform. We’ll now...

Synopsys (SNPS) is back in focus as investors weigh upbeat expectations for the next earnings report, with a positive Earnings ESP and strong analyst consensus serving as key drivers of recent stock interest. Over the past month Synopsys has seen a 1 month share price return of 9.46%, even as the 90 day share price return is down 22.27% and the 1 year total shareholder return has declined 31.41%, which points to improving short term momentum after a weaker stretch. Recent gains, including a 1...

In August 2026, Fizz Creations announced it had partnered with Hasbro to create a new range of portable digital versions of classic games including Monopoly, Operation, Yahtzee, and others, with the collection now expected to launch in early 2027. This collaboration highlights Hasbro’s push to extend its well-known board game brands into more accessible digital formats, potentially broadening audience reach and deepening engagement across its portfolio. We’ll now examine how expanding...

Mirion Technologies (MIR) has drawn attention after recent trading left the stock at US$14.71 as of 26 August 2026. Investors are weighing the move against its mixed short and longer term return profile. The recent decline in Mirion Technologies' 30-day share price return of 11.06% and 90-day share price return of 13.27% contributes to a year-to-date share price drop of 38.27%, while the 3-year total shareholder return of 75.96% remains positive. Compare Mirion Technologies' recent pullback...

HF Sinclair (DINO) is drawing fresh attention after reporting strong engagement from its updated Dinopay loyalty program, where game-linked rewards were associated with higher site visits and fuel purchases among actively participating customers. Even with the Dinopay update in focus, HF Sinclair’s share price has cooled slightly in the very short term, with a 1 day share price return of 2.04% and a 7 day share price return showing a 2.57% decline from the latest close of US$93.24. However,...

Century Aluminum stock has surged over the past few years, yet current valuation checks still lean on the cheap side. After a very strong multi year price move, the key issue is whether the recent pullback has left the stock trading below what its fundamentals suggest. Century Aluminum has delivered a very large return over the past 3 years, which puts extra focus on whether today’s price still offers a reasonable entry point for new money. Expectations for the company’s ability to convert...

Replimune Group (REPL) has drawn attention after reporting first quarter 2026 results, which showed a net loss of US$69.77 million, and appointing experienced oncology commercial leader Michelle DiNapoli as Chief Commercial Officer. The latest move in Replimune Group’s share price has been sharp, with a 1-month share price return of 62.89% and a 90-day share price return of 236.17% taking the stock to US$15.80. The 1-year total shareholder return of 178.17% contrasts with a 5-year total...

In August 2026, Paylocity Holding announced that director Craig Conway chose not to stand for re-election at the December 2026 annual meeting, while HireQuotient reported a partnership with Paylocity that cut manual recruiting effort and time-to-fill for Alliance Building Services using an AI-native applicant tracking system. This partnership highlights how Paylocity’s platform can replace fragmented recruiting tools with integrated, AI-enabled workflows that generate measurable efficiency...

POET Technologies (NasdaqCM:POET) reported its second quarter 2026 results on 13 August, with higher sales and a smaller quarterly net loss than the prior year. The results have drawn investor attention to possible operational shifts. The latest quarterly results appear to be feeding into a mixed price story for POET Technologies, with a 17.27% 1 month share price return and a 4.26% gain over the last trading day, while the 90 day share price return has declined 39.16%. Over a longer horizon,...

Coca-Cola stock has delivered an 88.7% total return over the past five years, yet current valuation checks suggest the shares are not an obvious bargain. The Discounted Cash Flow (DCF) estimate points to a price that is close to fair value, and market multiples point to a richer setup. Over the past 5 years Coca-Cola has returned 88.7%, which places current investors in the position of assessing whether that strong run already reflects much of the company’s quality and brand strength in the...

Qiagen stock has delivered a weak long term result over the past five years, while the valuation checks now send a mixed message as the intrinsic value estimate points to upside and the market multiples suggest the shares are not cheap. After this drift, investors are weighing whether the current price around US$43.65 already reflects the company’s prospects or still offers some margin for error. Qiagen shares have declined 20.9% over five years, which raises the question of whether...

A 30 year U.S. Saudi civil nuclear agreement now sits in front of Congress, and that mix of long term ambition and political risk is drawing fresh attention to nuclear power equipment and services stocks. Policy headlines could reshape expectations quickly, which creates both excitement and anxiety for investors watching this theme. This article walks through 3 stocks exposed to this news and how they might fit into your watchlist. The stocks in this article are a starting sample, while the...

Revvity (RVTY) is drawing fresh attention after a jump in options activity, with the September 18, 2026 $50 put ranking among the contracts with the highest implied volatility, and traders signaling expectations for a sizable stock move. The recent options activity follows a period of strong share price momentum for Revvity, with a 1-day share price return of 1.50%, a 7-day return of 9.75% and a 90-day return of 28.98%, while the 1-year total shareholder return is 37.22%. Scan how traders’...

MGM Resorts International has recently reported that its revenue has grown by only 2% annually over the past two years, while returns on capital have compressed, prompting investors to reassess how effectively its recent investments are contributing to profitability. This combination of modest revenue expansion and weakening capital efficiency raises questions about whether MGM’s current spending is truly enhancing its underlying business quality. Against this backdrop of slow revenue growth...

XP (NasdaqGS:XP) is back in focus after reporting second quarter 2026 results that included 8% revenue growth, a 117% jump in its corporate segment and return on equity of 22.5%. XP shares have responded to the recent earnings release and buyback updates, with a 1 week share price return of 12.37% and a year to date share price return of 10.01%. However, the 5 year total shareholder return is still down 58.42%, which suggests short term momentum has picked up while longer term holders remain...

Conference appearance puts UFP Technologies in focus UFP Technologies (UFPT) is set to present at the 17th Annual Midwest IDEAS Conference in Chicago on 26 August 2026, with investors watching for fresh insight into its medical and engineered products business. The conference appearance comes after a strong run in UFP Technologies, with the share price at US$304.21 and a 30-day share price return of 28.25% that adds to a 36.17% year to date rise. The 5-year total shareholder return of 334.65%...

The U.S. FDA has approved Ziihera (zanidatamab-hrii), a bispecific HER2-targeting antibody, as a first-line treatment for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma, triggering a US$250 million regulatory milestone payment from Jazz Pharmaceuticals to Zymeworks. This second FDA approval for zanidatamab in under two years further validates Zymeworks’ Azymetric bispecific antibody platform and strengthens its royalty- and...

Johnson & Johnson (NYSE: JNJ) received FDA approval for IMAAVY as the first treatment for adults with warm autoimmune hemolytic anemia, providing a new option for this rare blood disorder. The decision expands Johnson & Johnson's presence in rare diseases, with IMAAVY targeting patients who face limited existing therapies. In a separate development, a jury awarded a US$10 million verdict in a talc-related mesothelioma case against Johnson & Johnson, adding to its ongoing litigation...

Royal Caribbean Cruises (RCL) lifted its earnings guidance for 2026 and signaled confidence in revenue growth, even as higher fuel costs and Iran related safety concerns continue to affect bookings and operating expenses. Royal Caribbean Cruises shares trade at US$292.29 and have eased in the short term, with the 7 day share price return down 2.57%. However, the 90 day share price return of 6.22% and a very large 5 year total shareholder return of 263.30% suggest longer term momentum has been...

Recently, CNA Financial reported that while its premium volumes have been expanding, key insurance profitability indicators such as the combined ratio and core earnings have moved in an unfavorable direction. The company is leaning on selective underwriting, higher investment income, disciplined technology spending, and a solid capital position to support long-term earnings and ongoing dividend growth despite underwriting pressure. Next, we’ll examine how concerns over CNA’s underwriting...

RadNet (RDNT) has drawn investor attention after its recent share price moves, with the stock closing at US$76.86 and posting double digit total returns over the past month and past 3 months. Zooming out, RadNet’s recent share price momentum, including a 24.83% 30 day share price return and 42.76% 90 day share price return, sits alongside an 8.33% year to date share price return and a 135.26% 3 year total shareholder return. Together, these figures indicate building momentum from a longer...

Carpenter Technology (CRS) is in focus after updating investors on its planned US$400 million brownfield expansion. The project is expected to lift specialty alloys production capacity by 7% by fiscal 2028. Carpenter Technology’s update on the brownfield expansion comes after a sharp pullback, with the 30 day share price return down 19.48% and the 7 day return down 8.62%. This is despite the year to date share price return of 43.67% and the 1 year total shareholder return of 101.40%. Compare...

Eli Lilly stock has logged very strong gains over the past few years, yet the latest valuation checks send a mixed message about where fair value may sit. The intrinsic value estimate from a Discounted Cash Flow (DCF) model points to a meaningful discount, while the broader set of valuation checks does not present Eli Lilly as an obvious bargain or an obvious premium. Eli Lilly has delivered a return of about 399.8% over the past 5 years, which puts extra focus on whether the current share...